Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
Dexamethasone
Daratumumab
+1 more
Locations
113
United States
Lynn Cancer Center Boca Raton Regional Hospital, Lynn Cancer Institute
Boca Raton, Florida, United States
Emory University Winship Cancer Institute
Atlanta, Georgia, United States
University of Chicago Medical Center - Multiple Myeloma Research Consortium
Chicago, Illinois, United States
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Start Date
June 13, 2017
Primary Completion Date
July 14, 2019
Completion Date
April 15, 2022
Last Updated
May 9, 2025
NCT07523555
NCT06285318
NCT04973605
NCT05862012
NCT06138275
NCT07391657
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions